Physician profile
Rakesh Patel
NPI 1457312589
$787.44
in general payments reported to CMS, 2019-2025
15 companies · $68.56 in 2025
The $68.56 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.84 · 2020: $158 · 2021: $302 · 2022: $106 · 2023: $76.56 · 2024: $33.55 · 2025: $68.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $178.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $347.38 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $121.58 | 2021-2024 | Dupixent |
| Glaxosmithkline, LLC. | $49.72 | 2022-2025 | Nucala |
| Lilly USA, LLC | $44.27 | 2023 | Mounjaro |
| Intersect Ent, INC. | $39.10 | 2021 | |
| Merck Sharp & Dohme LLC | $32.36 | 2020-2022 | |
| Alk-Abello, INC | $31.40 | 2019-2021 | |
| Acclarent, INC | $25.92 | 2021 | |
| Stryker Corporation | $18.98 | 2022 | |
| Aerin Medical INC. | $16.20 | 2025 | |
| Medtronic USA, INC. | $15.51 | 2020 | |
| Abbvie INC. | $15.41 | 2024 | |
| Hikma Pharmaceuticals USA | $14.89 | 2025 | Ryaltris |
| Genzyme Corporation | $14.72 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$175,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.